ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2907

Loss of microRNA-146a Exacerbates Inflammatory Arthritis

Victoria Saferding1, Antonia Puchner2, Eliana Goncalvesalves3, Birgit Niederreiter4, Silvia Hayer4, Gernot Schabbauer5, Marije Koenders6, Josef Smolen1, Kurt Redlich3 and Stephan Blueml3, 1Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 5Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, 6Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: cytokines and inflammatory arthritis, MicroRNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

MicroRNA (MiR-) 146a is a key regulator of the innate immune response and has also been shown to suppress cancer development in myeloid cells. Elevated expression of miR-146a has been detected in synovial tissue of rheumatoid arthritis patients, but its role in the development of inflammatory arthritis is yet unknown.

Methods:

We induced K/BxN serum transfer arthritis in wild type and miR-146a-/- mice. As a second inflammatory arthritis model we crossed miR-146a deficient into hTNFtg mice. Disease severity was assessed clinically and histologically in both arthritis models. Blood of arthritis animals was analyzed by flow cytometry. Serum cytokine levels were measured by Elisa. 

Results:

Absence of miR-146a leads to increased clinical signs of the induced serum transfer arthritis. In line, higher serum levels of the proinflammatory cytokines IL12 and TNF were measured in miR146a deficient mice compared to wt mice. When we crossed miR-146a-/- mice into hTNFtg mice, while detecting no clinical difference between hTNFtg and miR-146a/hTNFtg mice, we found a significant increase in circulating CD11b+ myeloid cells as well as CD11c+ dendritic cells in blood of miR-146a-/-/hTNFtg mice compared to hTNFtg mice. Histological examination revealed a significant increase in synovial inflammation miR-146a-/-/hTNFtg mice compared to hTNFtg mice. Even more striking, miR-146a-/-/hTNFtg mice displayed a more than twofold increase in local bone destruction which was due to increased generation of osteoclasts in the tarsal joints of the mice. Measuring cytokine levels in serum, we show that IL-1β levels are increased in mice lacking miR-146a.

Conclusion:

These data clearly demonstrate a negative regulatory role of the miR-146a in inflammatory arthritis. During arthritis, miR-146a is centrally involved in the regulation of proinflammatory cytokines as well as local bone destruction. These results identify an important anti-inflammatory role of miR-146a, which might possibly be exploited for therapeutic purposes.


Disclosure:

V. Saferding,
None;

A. Puchner,
None;

E. Goncalvesalves,
None;

B. Niederreiter,
None;

S. Hayer,
None;

G. Schabbauer,
None;

M. Koenders,
None;

J. Smolen,
None;

K. Redlich,
None;

S. Blueml,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/loss-of-microrna-146a-exacerbates-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology